2026-2034年全球品牌學名藥市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，品牌非專利市場規模將達到 5,188.6 億美元，高於 2025 年的 3,047.8 億美元，預計從 2026 年到 2034 年的複合年成長率將達到 6.09%。

全球品牌非專利市場正經歷強勁成長，這主要得益於消費者對經濟實惠且品質可靠的藥品需求不斷成長。品牌非專利是指專利已過期、以品牌名稱銷售的藥品，它們價格親民且品質有保障。慢性病盛行率的上升以及降低成本的需求日益成長是推動市場擴張的主要因素。此外，新興市場醫療服務可近性的提高也促進了對品牌非專利的需求。

成長要素包括主要藥品專利到期以及人們對價格合理的醫療保健解決方案日益成長的需求。製藥公司正加大對品牌學名藥的投資，以維持其市場佔有率並拓展產品系列。消費者和醫療專業人員對品牌學名藥信心的增強也促進了市場成長。此外，政府推廣使用學名藥的措施也有助於市場擴張。

未來，隨著醫療保健覆蓋範圍的擴大和對價格合理治療方法的需求增加，品牌非專利市場預計將顯著成長。新興市場也有望因可支配收入的提高和健康意識的增強而帶來巨大的成長機會。此外，製劑和行銷策略的持續創新將進一步鞏固品牌非專利的全球市場地位。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球品牌學名藥市場：依藥物類別分類

• 市場分析、洞察與預測
• 烷化劑
• 抗代謝物
• 荷爾蒙藥物
• 抗高血壓藥物
• 降血脂藥物
• 抗憂鬱症
• 抗精神病藥物
• 抗癲癇藥物
• 其他

第5章：全球品牌學名藥市場：依應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 心血管疾病
• 神經系統疾病
• 消化系統疾病
• 皮膚病
• 急性和慢性疼痛
• 其他

第6章 全球品牌學名藥市場：依給藥途徑分類

• 市場分析、洞察與預測
• 外用
• 口服
• 腸外
• 其他

第7章 全球品牌學名藥市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球品牌學名藥市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Sanofi
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Apotex Inc
  • Viatris Inc

The Branded Generics Market size is expected to reach USD 518.86 Billion in 2034 from USD 304.78 Billion (2025) growing at a CAGR of 6.09% during 2026-2034.

The global branded generics market is experiencing strong growth due to the increasing demand for cost-effective yet reliable pharmaceutical products. Branded generics are off-patent drugs marketed under a brand name, offering quality assurance along with affordability. The rising prevalence of chronic diseases and the growing need to reduce healthcare costs are key factors driving market expansion. Additionally, increasing access to healthcare in emerging markets is boosting demand for branded generics.

Key growth drivers include patent expirations of major drugs and the growing focus on affordable healthcare solutions. Pharmaceutical companies are investing in branded generics to maintain market presence and expand their product portfolios. The increasing trust among consumers and healthcare providers in branded generics is also supporting market growth. Furthermore, government initiatives promoting the use of generic medicines are contributing to market expansion.

Looking ahead, the branded generics market is expected to grow significantly with expanding healthcare access and increasing demand for affordable treatments. Emerging markets are anticipated to offer substantial growth opportunities due to rising disposable incomes and healthcare awareness. Additionally, continuous innovation in drug formulations and marketing strategies will further strengthen the market position of branded generics globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-hypertensive
• Lipid Lowering Drugs
• Anti-depressants
• Anti-psychotics
• Anti-epileptics
• Others

By Application

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Gastrointestinal Diseases
• Dermatological Diseases
• Acute and Chronic Pain
• Others

By Route of Administration

• Topical
• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, Lupin, Sanofi, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Endo International plc, GlaxoSmithKline plc, Pfizer Inc, Apotex Inc, Viatris Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BRANDED GENERICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Alkylating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antimetabolites Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hormones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-hypertensive Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Lipid Lowering Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Anti-depressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Anti-psychotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Anti-epileptics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BRANDED GENERICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Gastrointestinal Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Dermatological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Acute and Chronic Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BRANDED GENERICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BRANDED GENERICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Application
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Application
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Application
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Application
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Application
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BRANDED GENERICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Teva Pharmaceutical Industries Ltd
  • 10.2.2 Lupin
  • 10.2.3 Sanofi
  • 10.2.4 Sun Pharmaceutical Industries Ltd
  • 10.2.5 Dr. Reddy's Laboratories Ltd
  • 10.2.6 Endo International Plc
  • 10.2.7 GlaxoSmithKline Plc
  • 10.2.8 Pfizer Inc
  • 10.2.9 Apotex Inc
  • 10.2.10 Viatris Inc